Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung (NCT03808662)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Age 18 or older
2. Willing and able to provide informed consent
3. Metastatic disease detected on imaging and histologically confirmed: Triple negative breast cancer TNBC (ER \<1%, PR \<1%, her-2-neu 0- 1+ by IHC or FISH-negative or as determined by MD discretion) OR NSCLC (without known EGFR mutation or ALK/ROS1 rearrangement) OR Other high-risk breast cancer (per physician's discretion) progressed on hormone or systemic therapy, regardless of ER/HER2 status OR NSCLC with EGFR, ALK, or ROS1 targetable molecular alterations with disease progression on first-line tyrosine kinase inhibitor Note:
4. Biopsy of metastasis prior to enrollment is per treating physician's discretion per standard of care. It is preferred but not required.
5. These patients are selected for the study given the similar survival outcomes when given standard of care therapies
6. Patient has received at least first-line prior treatment with systemic therapy (either cytotoxic or targeted, including maintenance therapies).
7. Patients who received prior immunotherapy are allowed.
8. Patients who had any prior radiation therapy near or overlapping with the oligoprogressive sites are allowed to enroll.
9. Patients with the following medical conditions precluding them from participating in other systemic therapy or drug trials are allowed:
10. active liver disease, including viral or other hepatitis, or cirrhosis
11. any other significant medical condition not under control, including any acute coronary syndrome within the past 6 months.
12. a permanent pacemaker

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (10 Sites)

• Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
• Memorial Sloan Kettering Monmouth — Middletown, New Jersey
• Memorial Sloan Kettering Bergen — Montvale, New Jersey
• Memorial Sloan Kettering Commack — Commack, New York
• Memorial Sloan Kettering Westchester — Harrison, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Memorial Sloan Kettering Rockville Centre — Rockville Centre, New York
• Memorial Sloan Kettering Nassau — Uniondale, New York
• Fred Hutchinson Cancer Research Center (Data Analysis Only) — Seattle, Washington
• Princess Margaret Hospital/Ontario Cancer Institute (Data Analysis Only) — Toronto, Ontario

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.